BCL2 and acute myeloid leukemia: Recent research has attributed the efficacy of a novel combination of pegylated crisantaspase and the BCL-2 inhibitor venetoclax in complex karyotype AML to global translation inhibition by enhancing 4EBP/eIF4E interaction on the cap-binding complex [38].